<DOC>
	<DOCNO>NCT00239239</DOCNO>
	<brief_summary>The purpose study characterize pharmacokinetics/pharmacodynamics ( PK/PD ) darbepoetin alfa administer subcutaneous ( SC ) dose 0.45 mcg/kg three time weekly ( TIW ) anemic patient non-myeloid malignancy receive multicycle chemotherapy .</brief_summary>
	<brief_title>Fractionated Dosing Study : Study Evaluate Darbepoetin Alfa Treatment Anemia Subjects With Non-Myeloid Malignancies</brief_title>
	<detailed_description />
	<mesh_term>Anemia</mesh_term>
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Darbepoetin alfa</mesh_term>
	<criteria>Nonmyeloid malignancy Currently receive 3week cyclic chemotherapy treatment minimum 2 additional cycle chemotherapy planned time enrollment Anemia predominately due cancer chemotherapy ( Hb &gt; = 9.0 &lt; 11.0 g/dL ) time screen 18 year age old time screen Eastern Cooperative Oncology Group ( ECOG ) score 02 Adequate liver kidney function Known primary hematologic disorder , could cause anemia , nonmyeloid malignancy History chronic myeloid leukemia ( CML ) , acute myeloid leukemia ( AML ) , myelodysplastic syndrome ( MDS ) , acute lymphocytic leukemia ( ALL ) , hairy cell leukemia , Burkitt 's lymphoma , lymphoblastic lymphoma Serum folate &lt; = 2.0 ng/mL vitamin B12 &lt; = 200 pg/mL screening ( anemia relate nutritional deficiency ) Iron deficiency [ transferrin saturation ( TSAT ) &lt; 15 % serum ferritin &lt; 10 ng/mL ] screen Other diagnosis related cancer chemotherapy , cause anemia ( ie , hemolysis , bleeding , sickle cell anemia ) Clinically significant inflammatory disease determine investigator ( eg , rheumatoid arthritis , Crohn 's disease ) Clinically significant comorbid medical psychiatric condition may impact subject safety confound ability evaluate study endpoint determine investigator Unstable uncontrolled cardiac disease condition ( ie , angina , congestive heart failure , cardiac arrhythmia ) Diastolic blood pressure &gt; 100 mmHg screen Known hypersensitivity erythropoieticstimulating protein ( ESPs ) excipients Known history pure red cell aplasia Known positive antibody response ESP Use investigational agent approve indication previous 30 day prior enrollment ESP therapy ( i.e. , recombinant human erythropoietin [ rHuEPO ] darbepoetin alfa ) within 21 day prior screen screen first dose study drug RBC transfusion ( ) within 21 day prior screen Pregnant breastfeed woman Previously enrol study Known HIV , hepatitis B C positive Any disorder would compromise ability subject give write informed consent comply study requirement procedure</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2010</verification_date>
	<keyword>Non-myeloid malignancy</keyword>
	<keyword>Chemotherapy-induced anemia</keyword>
	<keyword>Oncology</keyword>
	<keyword>Clinical Trials</keyword>
	<keyword>Pharmacokinetics</keyword>
	<keyword>Darbepoetin alfa</keyword>
	<keyword>Aranesp</keyword>
	<keyword>Amgen</keyword>
</DOC>